Outcome of the Board Meeting
BAJAJHCARE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Bajaj Healthcare reported FY2026 revenue from operations of Rs 61,103 lakhs, up 12.6% from Rs 54,260 lakhs in FY2025, showing steady top-line growth. However, profit after tax from continuing operations dropped sharply to Rs 2,131 lakhs from Rs 4,293 lakhs — a 50% decline — mainly due to an exceptional charge of Rs 3,325 lakhs arising from reversal of income from a failed technical know-how arrangement with a Middle East customer affected by regional instability. Total PAT including discontinued operations fell to Rs 1,577 lakhs from Rs 3,950 lakhs (down 60%). The board recommended a 30% dividend (Rs 1.50 per share of Rs 5 face value), appointed JCR & Co. LLP as internal auditors for FY2027, and reappointed V.J. Talati & Co. as cost auditors. Statutory auditors Walker Chandiok & Co LLP issued an unmodified opinion. The company also completed conversion of 20.79 lakh convertible warrants into equity shares, raising Rs 5,271 lakhs (balance 75% of issue price), bringing total equity funds raised to Rs 16,226 lakhs.
The large exceptional item reversal has severely compressed FY2026 profits, though underlying operations grew revenue by 12.6%. The dividend recommendation provides some support for shareholders, but the significant PAT decline and uncertain Middle East exposure may weigh on the stock near term.